Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Cerilliant
Merck
Fuji
Express Scripts
Chinese Patent Office
Deloitte
Colorcon
Cantor Fitzgerald

Generated: August 17, 2018

DrugPatentWatch Database Preview

Chemo Research Sl Company Profile

« Back to Dashboard

What is the competitive landscape for CHEMO RESEARCH SL, and when can generic versions of CHEMO RESEARCH SL drugs launch?

CHEMO RESEARCH SL has six approved drugs.

There are six US patents protecting CHEMO RESEARCH SL drugs.

There are thirty-two patent family members on CHEMO RESEARCH SL drugs in seventeen countries and one supplementary protection certificate in one country.

Summary for Chemo Research Sl
International Patents:32
US Patents:6
Tradenames:5
Ingredients:5
NDAs:6

Drugs and US Patents for Chemo Research Sl

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chemo Research Sl BENZNIDAZOLE benznidazole TABLET;ORAL 209570-001 Aug 29, 2017 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Chemo Research Sl NUVESSA metronidazole GEL;VAGINAL 205223-001 Mar 24, 2014 RX Yes Yes 8,877,792 ➤ Try a Free Trial Y ➤ Try a Free Trial
Chemo Research Sl ECOZA econazole nitrate AEROSOL, FOAM;TOPICAL 205175-001 Oct 24, 2013 RX Yes Yes 5,993,830 ➤ Try a Free Trial Y ➤ Try a Free Trial
Chemo Research Sl NUVESSA metronidazole GEL;VAGINAL 205223-001 Mar 24, 2014 RX Yes Yes 8,946,276 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Chemo Research Sl Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0021 Belgium ➤ Try a Free Trial PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Accenture
Queensland Health
UBS
Deloitte
Mallinckrodt
Cantor Fitzgerald
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.